A method for predicting the effectiveness of glucocorticoid therapy in patients with moderate COVID-19 based on simple clinical and laboratory data
- 27 October 2022
- journal article
- research article
- Published by ECO-Vector LLC in Epidemiology and Infectious Diseases
- Vol. 27 (2) , 75-88
Abstract
BACKGROUND: In patients hospitalized with coronavirus infection (COVID-19), methods for predicting the effectiveness of anti-inflammatory therapy have important practical implications for optimizing treatment and outcomes. To date, several indicators of COVID-19 patients (age, comorbidities, and laboratory criteria for the intensity of inflammation) have been identified to indicate a high probability of a severe course and a risk of an adverse outcome. However, the problem of predicting the effectiveness of anti-inflammatory therapy in patients with moderate COVID-19 is not well understood. AIM: This study aimed to develop a predictive model to determine the effectiveness/failure of anti-inflammatory therapy with glucocorticosteroids (GCS) in patients with moderate COVID-19 to improve the treatment outcomes of hospitalized patients. MATERIALS AND METHODS: This study retrospectively analyzed electronic medical record data of all patients admitted consecutively from October 1, 2020, to January 31, 2021. The study included 71 patients with probable (clinically confirmed) and confirmed (laboratory) COVID-19 of moderate course, with characteristic changes in the lungs according to computed tomography of the chest organs (CT-CCT). Given the severity of the course, all study patients were prescribed GCS in accordance with the current version of the Interim Guidelines of the Ministry of Health of the Russian Federation. RESULTS: A total of 71 patients were studied, and 53 (74.7%) of them did not require an escalation of anti-inflammatory therapy, which is regarded as an effective use of corticosteroids as an anti-inflammatory therapy (group 1). In the remaining 18 patients, the use of corticosteroids for an average of 5.5 (36) days did not have a definite clinical effect and required the additional use of monoclonal antibodies (MCA) to interleukin-6 (IL-6) or to its receptor (group 2). Using logistic regression analysis and receiver operating characteristic analysis, a mathematical model was developed and evaluated to predict the outcome of anti-inflammatory corticosteroid therapy in patients with moderate COVID-19. As risk factors, indicators that had significant differences in the studied groups before GCS initiation were selected: number of lymphocytes, platelets, and body temperature. The quality of the constructed model is assessed as very good, and the optimal cutoff point is 0.697. The sensitivity index of the model is 81.1%, and the specificity index is 72.2%. CONCLUSIONS: The mathematical model makes it possible to predict the effectiveness of GCS therapy according to the number of lymphocytes, platelets, and body temperature. The mathematical model is adequate and has a high sensitivity and specificity.Keywords
This publication has 24 references indexed in Scilit:
- Design, synthesis and characterization of novel Ni(II) and Cu(II) complexes as antivirus drug candidates against SARS-CoV-2 and HIV virusJournal of Molecular Structure, 2022
- A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitorsActa Pharmacologica Sinica, 2021
- Dexamethasone in Hospitalized Patients with Covid-19New England Journal of Medicine, 2021
- Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumoniaAmerican Journal of Infection Control, 2021
- Clinical manifestations of COVID-19 in the general population: systematic reviewWiener klinische Wochenschrift, 2020
- Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19JAMA, 2020
- Utilization of machine-learning models to accurately predict the risk for critical COVID-19Internal and Emergency Medicine, 2020
- Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19Clinical Infectious Diseases, 2020
- Mechanism of thrombocytopenia in COVID-19 patientsAnnals of Hematology, 2020
- Corticosteroid prevents COVID-19 progression within its therapeutic window: a multicentre, proof-of-concept, observational studyEmerging Microbes & Infections, 2020